Mercator MedSystems
  • Home
  • Corporate Mission Officers and Directors
  • Bullfrog Micro-Infusion Device Blowfish Transbronchial Micro-Infusion Device
  • Peripheral Artery Disease Bronchial Carcinoma Peer-Reviewed Publications
  • TANGO LIMBO DANCE BROADWAY Other Trials
  • Mercator MedSystems Receives $11M in Series D Equity Financing Led by Shenzhen Salubris MedTech Strategist Nov 27, 2017 Mercator MedSystems Announces Completion of Enrollment in the LIMBO-ATX Trial Mercator MedSystems Announces First Enrollment in the TANGO Trial for BTK Vascular Disease Clinical Trial Data Presented from Mercator MedSystems' DANCE Trial at ISET and LINC Mercator Bullfrog Device Being Used in New Proteon Therapeutics Study Late-Breaking Clinical Trial Data Presented from Mercator MedSystems' DANCE Trial at VIVA 2016 LIMBO-ATX Trial Begins in United States LIMBO-PTA Trial Begins in Germany Trent Reutiman Named CEO Archives
  • Contact
Mercator MedSystems
  • Home/
  • About Us/
    • Corporate Mission
    • Officers and Directors
  • Products/
    • Bullfrog Micro-Infusion Device
    • Blowfish Transbronchial Micro-Infusion Device
  • Science and Technology/
    • Peripheral Artery Disease
    • Bronchial Carcinoma
    • Peer-Reviewed Publications
  • Clinical Trials/
    • TANGO
    • LIMBO
    • DANCE
    • BROADWAY
    • Other Trials
  • News/
    • Mercator MedSystems Receives $11M in Series D Equity Financing Led by Shenzhen Salubris
    • MedTech Strategist Nov 27, 2017
    • Mercator MedSystems Announces Completion of Enrollment in the LIMBO-ATX Trial
    • Mercator MedSystems Announces First Enrollment in the TANGO Trial for BTK Vascular Disease
    • Clinical Trial Data Presented from Mercator MedSystems' DANCE Trial at ISET and LINC
    • Mercator Bullfrog Device Being Used in New Proteon Therapeutics Study
    • Late-Breaking Clinical Trial Data Presented from Mercator MedSystems' DANCE Trial at VIVA 2016
    • LIMBO-ATX Trial Begins in United States
    • LIMBO-PTA Trial Begins in Germany
    • Trent Reutiman Named CEO
    • Archives
  • Contact/
Mercator MedSystems

Think outside the lumen

Mercator Bullfrog Device Being Used in New Proteon Therapeutics Study

Mercator MedSystems
  • Home/
  • About Us/
    • Corporate Mission
    • Officers and Directors
  • Products/
    • Bullfrog Micro-Infusion Device
    • Blowfish Transbronchial Micro-Infusion Device
  • Science and Technology/
    • Peripheral Artery Disease
    • Bronchial Carcinoma
    • Peer-Reviewed Publications
  • Clinical Trials/
    • TANGO
    • LIMBO
    • DANCE
    • BROADWAY
    • Other Trials
  • News/
    • Mercator MedSystems Receives $11M in Series D Equity Financing Led by Shenzhen Salubris
    • MedTech Strategist Nov 27, 2017
    • Mercator MedSystems Announces Completion of Enrollment in the LIMBO-ATX Trial
    • Mercator MedSystems Announces First Enrollment in the TANGO Trial for BTK Vascular Disease
    • Clinical Trial Data Presented from Mercator MedSystems' DANCE Trial at ISET and LINC
    • Mercator Bullfrog Device Being Used in New Proteon Therapeutics Study
    • Late-Breaking Clinical Trial Data Presented from Mercator MedSystems' DANCE Trial at VIVA 2016
    • LIMBO-ATX Trial Begins in United States
    • LIMBO-PTA Trial Begins in Germany
    • Trent Reutiman Named CEO
    • Archives
  • Contact/

Proteon Therapeutics Announces First Patient Dosed in Phase 1 Study Evaluating Vonapanitase for the Treatment of Peripheral Artery Disease Below the Knee [click to view]

Copyright Mercator MedSystems 2019. All rights reserved.